We are developing a novel therapeutic discovery and care delivery platform for Alzheimer's disease.
Applied Cognition's mission is to slow disease progression in asymptomatic Alzheimer’s patients using unique new methods to diagnose, monitor and deliver treatment.
Cost of supportive care per year for Medicare in the U.S.
Total cost per patient in the last 5 years of life with dementia.
3x higher spent by Medicare on a patient with AD compared to all other seniors.
Managing Alzheimer's disease is currently a significant cost burden.
47 million Americans have asymptomatic Alzheimer's disease.
Alzheimer’s is the most expensive disease in the U.S., costing more than cancer care and heart disease, yet no treatments exist to slow or prevent the progression of the disease.
The New Science of Alzheimer's
Recent breakthroughs in understanding the mechanism of Alzheimer’s disease and the interplay between neurophysiological, cerebral vasculature and neurovascular coupling have emerged.
This interplay is responsible for clearing toxic amyloid and tau waste.
Innovations in microtechnology, material sciences and AI have allowed us to develop unobtrusive, wearable sensors to monitor disease progression.
Continuously monitoring these targets and interventions that engage these targets will enable us to slow or halt disease progression.
Completed internal studies
We are validating our platform in clinical trials and with real-world data.
We have validated our device's ability to instrument targets in early studies and are demonstrating our platform's ability to diagnose, predict and slow disease progression in clinical trials.
Executive Chairman &
Jake is a serial entrepreneur with a decade-long interest in using connected devices and data to improve work, health, and athletic performance and a history of converting his interests into successful companies across a wide range of industries from media to healthcare.
Our Team & Collaborators
We're a unique team of microtechnology engineers, material scientists, product and industrial designers, mechanical and software engineers, clinical scientists and Alzheimer's neurologists who come from some of the most highly reputed institutions in the nation, as seen here.
Our Scientific Advisory Board
We collaborate with outstanding physician scientists and neuroscientists leading research in neurodegeneration and with pioneering computer scientists and electrical engineers working in AI and microtechnology.